Investment Rating - The report does not explicitly state an investment rating for the synthetic biology industry Core Insights - The synthetic biology sector is experiencing a global technological revolution, providing innovative solutions to major challenges such as health, climate change, and food security, as highlighted by the National Development and Reform Commission's "14th Five-Year Plan for Bioeconomic Development" [4] - The Huazhong Securities Synthetic Biology Index, which includes 58 companies across various sectors, has seen a decline of 3.42% recently, underperforming compared to the Shanghai Composite Index and the ChiNext Index [5][17] - The first local regulations for synthetic biology manufacturing were passed in Changde, Hunan, aimed at promoting industry development and addressing issues like talent shortages and approval efficiency [8][10] Summary by Sections 1.1 Secondary Market Performance - The synthetic biology sector's stocks have shown poor performance, with a recent decline of 3.42%, ranking 32nd among sectors [17] - The top-performing companies include Jincheng Pharmaceutical (+11%), Xinhai Hengli (+10%), and Dongbao Biological (+7%) [18] 1.2 Company Business Progress - Kexin Pharmaceutical's CAR-T therapy targeting Claudin18.2 has received regulatory acceptance for market application, offering new treatment options for advanced gastric cancer patients [23] - Angel Yeast announced a significant investment of 5.56 billion yuan to expand its biological manufacturing center and enhance its product lines [23] - Internationally, Covestro acquired Swiss film technology company Pontacol to strengthen its specialty materials business [25] 1.3 Industry Financing Tracking - The synthetic biology sector is witnessing accelerated financing, with nearly 100 companies completing new funding rounds since the beginning of 2025 [31] - Zhejiang Rongrui Technology completed nearly 100 million yuan in Pre-A financing, focusing on green biological manufacturing [31] - Avantium, a Dutch biobased PEF company, secured 10 million euros to alleviate short-term liquidity pressures [31]

Group 1 - The company plans to issue A-shares to specific investors, pending approval from the Shenzhen Stock Exchange and the China Securities Regulatory Commission (CSRC) [2][3][4] - The final issuance price will be no less than 85% of the average trading price of the company's shares over the 20 trading days prior to the pricing date [3][4][5] - The total number of shares to be issued will not exceed 25% of the company's total share capital, amounting to a maximum of 83,530,821 shares [5][6] Group 2 - The funds raised will be allocated to specific projects, including the construction of a production base for amino acids and an enhancement project for raw materials [6][7] - The company may adjust the investment priorities and amounts based on the actual net amount raised and project urgency if the net proceeds are less than planned [6][7] - The company has committed to using the raised funds in compliance with relevant regulations and will replace any pre-invested funds once the raised funds are available [6][7] Group 3 - The company operates in the pharmaceutical industry, which is subject to strict regulatory oversight from various government bodies, including the National Medical Products Administration and the National Healthcare Security Administration [19][20] - The pharmaceutical industry is characterized by significant competition and regulatory challenges, including drug approval processes and pricing regulations [19][20][21] - The company’s business encompasses pharmaceutical distribution, manufacturing, and health services, with a focus on both commercial and industrial sectors [19][20]

Core Viewpoint - The article highlights the upcoming "Youth Forum on Biomanufacturing" scheduled for August 20 in Ningbo, Zhejiang, as part of the SynBioCon 2025 event, aimed at promoting innovation and collaboration in the field of synthetic biology and biomanufacturing [2][3]. Group 1: Event Details - The "Youth Forum on Biomanufacturing" will focus on addressing scientific issues, solutions, achievements, scalability, and future directions in the research field [3]. - The event will take place on August 20, 2025, with limited seating available (only 30 seats) [6]. - Participants can choose to register for either the Youth Forum or the Technology Achievement Showcase [6]. Group 2: Participation and Contributions - The event encourages universities and research institutions to apply for sharing their innovative achievements [4]. - SynBioCon 2025 will also feature a "Technology Achievement Showcase" to publicly collect 100 innovative achievements and projects in the field of synthetic biology and biomanufacturing for on-site display and networking [6]. Group 3: Organizers and Previous Events - The event is organized by Ningbo Detaizhongyan Information Technology Co., Ltd. (DT New Materials) and co-organized by Ningbo Meisai Biological Engineering Co., Ltd. [11]. - Previous editions of the SynBioCon were successfully held in 2022, 2023, and 2024 in Ningbo, showcasing the growing interest and development in the field [13].

Core Viewpoint - Meihua Biotech has successfully completed the acquisition of the amino acid business and assets from Concord Fermentation, enhancing its product and business structure in the synthetic biology sector [1]. Group 1: Acquisition Details - The acquisition was finalized on July 1, 2025, with a transaction price of approximately 16.8 billion Japanese yen, equivalent to about 833 million RMB [1]. - The final transaction price was adjusted based on the cash reserves and working capital of the target assets at the time of closing, which included an estimated cash amount of 11.3 billion Japanese yen (approximately 560 million RMB) [1]. - Concord Fermentation is recognized as a leader in biotechnology and fermentation, focusing on high-quality amino acids and other synthetic biology products [1]. Group 2: Business Expansion - The acquisition allows Meihua Biotech to diversify its product offerings by adding various new amino acid products and strains, enhancing its fermentation and refinement capabilities for high-value pharmaceutical amino acids [1]. - The company will also gain production capabilities and intellectual property for three types of Human Milk Oligosaccharides (HMO) through the integration of a precision fermentation platform [1]. - The acquisition supports the company's strategy to expand its industrial footprint internationally by acquiring multiple domestic and foreign operational entities [1]. Group 3: Financial Performance - In Q1 2025, the feed amino acid segment generated revenue of 2.939 billion RMB, accounting for approximately 46.9% of total revenue, marking a year-on-year increase of 6.68% [2]. - The growth in this segment is attributed to the rise in both volume and price of lysine, as well as increased sales of threonine, positioning it as a potential new growth driver for the company [2].

中化新网讯 6月26日，中国科学院院士、天津大学教授元英进，合成生物学领军者约翰·康伯斯，欧洲科 学院院士、曼彻斯特大学教授蔡毅之，与天津大学历届iGEM团队成员在津共聚"iGEM中国20年"学术论 坛，共同探讨合成生物学未来发展方向。 约翰·康伯斯在活动中做了题为"合成生物学：通过基因读、写、编辑打造可持续的未来"的报告。他指 出，过去十年间，合成生物学已从一个小众科学领域发展成为潜力巨大的活跃产业，从基因编辑到合成 基因组学等关键技术的进步，推动了制药、农业、材料及能源等行业的可持续发展与创新。他还表示， 初创企业与风险投资的进入起到了加速创新的作用，有助于构建可持续的生物经济体系，学术界、产业 界与政府间的全球协作也在加速这一进程。 天津大学作为最早把这项国际赛事引入中国的高校，也开设了"基因组设计合成"这门本科生课程，并于 2017年设立合成生物学专业，开始招收本科生；2025年成立合成生物学院。经过十几年的发展，天津大 学合成生物学从零起步走到世界科技前沿，牵头建设合成生物技术全国重点实验室，近三年合成生物学 领域研究论文发表量居全球第一。 iGEM竞赛是合成生物学领域的国际顶级学术性竞赛，最早由美 ...

Core Viewpoint - Meihua Biotechnology is advancing steadily in the synthetic biology sector through diversified expansion and deepening development, highlighted by its recent acquisition of assets from Kyowa Hakko Bio, which will enhance its amino acid product lines and operational capabilities [1][2]. Group 1: Acquisition Details - The acquisition agreement between Meihua Biotechnology and Kyowa Hakko Bio is set to be completed by July 1, 2025, with a final transaction value of approximately 16.8 billion yen, equivalent to about 833 million yuan [1]. - The cash reserves of the target assets are estimated at around 11.3 billion yen, or approximately 560 million yuan, as of June 30, 2025 [1]. Group 2: Product and Market Expansion - Post-acquisition, the company will introduce various new amino acids and fermentation strains, including arginine, histidine, serine, citrulline, ornithine, and hydroxyproline, along with patents related to these amino acids [2]. - The transaction will enable the company to extend its industrial chain, enhancing its fermentation and refinement capabilities for high-value pharmaceutical-grade amino acids [2]. Group 3: Strategic Positioning - Meihua Biotechnology aims to implement its overseas development strategy through this acquisition, gaining multiple domestic and international production entities [2]. - The company will also acquire the ability to produce three types of HMO products through a precision fermentation platform, along with the associated intellectual property rights [2]. Group 4: Industry Background - Kyowa Hakko Bio has a long-standing reputation in the global synthetic biology field, with over 70 years of technological expertise and numerous patents in amino acid and HMO product development [3]. - The company has successfully commercialized various amino acids and HMO products, including 2'-fucosyllactose, 3'-sialyllactose, and 6'-sialyllactose [3]. Group 5: Financial Performance - Meihua Biotechnology reported a revenue of 25.069 billion yuan and a net profit of 2.74 billion yuan for 2024, with a significant year-on-year growth of 35.52% in net profit for the first quarter of 2025 [3].

Core Insights - The acquisition of assets from Kiri Holdings by Meihua Biological has been successfully completed, with a final transaction price of approximately 16.8 billion yen, equivalent to about 833 million yuan [1] - The acquisition will enhance Meihua Biological's business structure, product offerings, and industry layout, particularly in the high-value-added pharmaceutical amino acid sector [2] Group 1: Acquisition Details - The acquisition includes food amino acids, pharmaceutical amino acids, and human milk oligosaccharides (HMO) business and assets [1] - The final transaction price was adjusted based on the cash reserves and working capital of the acquired assets, with an estimated cash reserve of about 11.3 billion yen, or approximately 560 million yuan [1] Group 2: Business Expansion - Post-acquisition, Meihua Biological will gain access to various new amino acid strains and patents, enhancing its fermentation and refinement capabilities [2] - The company will also introduce production capabilities for three types of HMO products and strengthen its intellectual property system [2] Group 3: Financial Performance - In Q1 2025, the feed amino acid segment generated revenue of 2.939 billion yuan, accounting for approximately 46.9% of total revenue, marking a year-on-year increase of 6.68% [2] - The segment is expected to become a new growth driver for the company, following its transformation from a "monosodium glutamate king" to a "synthetic biology giant" [2] Group 4: Market Outlook - Institutional investors maintain a positive outlook on Meihua Biological, with projected net profit for 2024 at 2.740 billion yuan, a year-on-year decrease of 13.85% [3] - However, Q1 2025 net profit reached 1.019 billion yuan, reflecting a year-on-year increase of 35.52% and a quarter-on-quarter growth of 36.72%, indicating robust performance and future growth potential [3]

Core Viewpoint - The article discusses the challenges and advancements in the industrialization of natural macromolecular active substances, highlighting a novel bioreactor developed to enhance fermentation processes for these substances [1][2][4]. Group 1: Challenges in Industrialization - Natural macromolecular active substances, such as polyamino acids, functional proteins, and microbial polysaccharides, face extraction difficulties due to their high molecular weight and complex conformations [1]. - The fermentation process of these substances is characterized by high viscosity, high oxygen demand, and high energy consumption, which complicates production [2][4]. - The accumulation of products during fermentation leads to high-viscosity non-Newtonian fluid characteristics, creating barriers that inhibit oxygen and nutrient metabolism, thus limiting yield improvements [1]. Group 2: Innovations in Bioreactor Technology - A new microbubble bioreactor platform has been developed using laser sintering 3D printing technology and computational fluid dynamics principles, aimed at overcoming the challenges of high-viscosity fermentation processes [2][4]. - This bioreactor design allows for the transition from macro to micro bubbles (less than 100 μm), significantly increasing the contact surface area between microorganisms and oxygen, thereby enhancing oxygen transfer efficiency by 120%-135% [4]. - The energy efficiency of the fermentation process is improved by 1.6 to 2.9 times compared to traditional bioreactors [4]. Group 3: Performance Improvements in Fermentation - The new bioreactor technology has been validated in a 7 L fermentation tank for the production of γ-polyglutamic acid (γ-PGA), achieving over a 40% increase in yield [5]. - The technology has also demonstrated versatility, with fermentation yields for other macromolecules such as mussel adhesive protein, panibacterial polysaccharide, welan gum, β-glucan, and ε-polylysine increasing by 79%, 58%, 39%, 50%, and 43% respectively [5]. Group 4: Implications for the Industry - This innovative research provides a reference and technical support for the efficient biosynthesis and industrial application of macromolecular active substances, as well as insights for enhancing fermentation processes in other synthetic biology products [7]. - The advancements in biomanufacturing are expected to contribute to the ongoing development of the synthetic biology industry, particularly in the context of green manufacturing and sustainable practices [7].

Core Insights - The article discusses the launch of the "Synthetic Human Genome Project" (SynHG), led by Professor Jason Chin from the University of Oxford, with funding of £10 million from the Wellcome Trust, aiming to chemically synthesize a complete human genome [1][2] - The project is expected to develop foundational tools and methods that will support future research in synthetic biology, potentially leading to new discoveries about how cells utilize their genomes [2][3] Group 1: Project Overview - SynHG is the first of its kind globally, with a goal to construct a complete human genome through chemical synthesis [1] - The project aims to establish a technical framework within five years and to synthesize a complete human chromosome within 5-10 years, facing significant scientific challenges [2] Group 2: Scientific Implications - Professor Jason Chin emphasizes that the ability to synthesize large genomes could fundamentally change the understanding of genomic biology and expand the capabilities of biotechnology and medicine [3] - The project is not about creating life but focuses on understanding gene expression regulation mechanisms [3] Group 3: Future Directions and Events - The upcoming "Synthetic Biology and Green Bio-Manufacturing Conference" (SynBioCon 2025) will take place from August 20-22 in Ningbo, Zhejiang, focusing on the intersection of AI and bio-manufacturing [4][5] - The conference will explore trends in bio-manufacturing, innovative technologies, and the potential for technology transfer and talent acquisition in the industry [4]

Core Insights - Nearshore Protein (688137) is focusing on protein tool innovation and applications, providing timely and high-quality products and services for innovative drug development companies and other life health application enterprises [1][2] - The company reported a revenue of 128 million yuan for the fiscal year 2024, a year-on-year decrease of 16.73%, and a net profit attributable to the parent company of -54.4163 million yuan, a significant decline of 523.68% [1] Group 1 - The company has increased investments in product quality improvement and business expansion to adapt to market changes and achieve high-quality development [1] - Nearshore Protein has made substantial progress in expanding its overseas market presence, establishing international professional teams in key markets such as the United States and Europe [2] - The global sales network now covers multiple major countries and regions, with a focus on core customer groups including international pharmaceutical companies, biotech firms, and research institutions [2] Group 2 - The company is enhancing the application of AI in the life sciences sector while advancing the industrialization of various synthetic biology projects, including collagen raw materials [2] - Nearshore Protein is actively seeking collaboration investments and acquisitions related to its main business to integrate upstream and downstream industry chain resources, enriching its industrial layout and creating a new industry ecosystem [2]